CDKN2A and astrocytoma (excluding glioblastoma): Further research based on the findings is necessary to validate the efficacy of H3K27me3/EZH2 for predicting the malignancy of astrocytoma, IDH-mutant and to explore the association of H3K27me3/EZH2 with the molecular features of CDKN2A/B HD or the radiological characteristics.